Compare AbCellera Biologics Inc (ABCL) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.51. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ABCL | YMAG | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $15.98 |
52-Week Low | $2.78 | $11.00 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
YMAG trades at $11.70, up 2.01% today, but technical indicators signal bearish momentum with resistance at $12. The ETF maintains weekly dividend distributions, though recent analysis highlights concerns about NAV decay from its synthetic covered call strategy on Magnificent Seven stocks. Mixed sentiment prevails with some analysts seeing tactical opportunities in rangebound markets while others cite limited upside potential.
Outlook remains cautious due to structural NAV erosion risks and high expense ratios. The fund's performance depends heavily on volatility monetization from its underlying option strategy, creating both income opportunities and capital depreciation risks in trending markets. Investors should weigh the high yield against potential long-term underperformance versus the broader market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
